Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics PLC technology passes crucial milestone after independent test

Its SkinBiotix cream was assessed for cellular toxicity
Woman stroking face
Its SkinBiotix cream is being developed as a cosmetic initially, though it has potential medical uses too

SkinBioTherapeutics PLC (LON:SBTX) said its flagship technology had passed a key safety test as it updated on progress.

Its SkinBiotix cream was assessed for cellular toxicity and specifically for adverse biological reactions from mammalian cell cultures.

READ: SkinBioTherapeutics - New listing in the emerging field of the human microbiome has multiple value trigger points

SkinBio said no cytotoxicity was observed; in other words there was no malformation of cells, or cell degeneration.

The data backed up in-house results compiled by the company, which listed on the stock market in April.

“This was one of the key milestones to pass and was highlighted as such at the IPO,” said chief executive, Dr Catherine O’Neill.

“Its passing marks a critical step in our progression and the transitioning of the technology into human validation studies.”


The SkinBiotix platform is protected by three patent families and 18 patent applications and is supported by a host of peer-reviewed academic publications and has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.

From that it is developing three products that manage, protect and restore the body’s largest organ.

READ: SkinBioTherapeutics 'starting early conversations with potential commercial partners'

First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.

The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes.

Three phases

Pilot formulation has begun with an outside partner with expertise in cosmetics. Phase one of three is complete: testing the solubility and preservative requirements of the technology. Phase two, identifying a final blend for testing, is currently underway.

At the same time, a study has determined the cream is best applied every five hours for protection against infection.

In the update, SkinBioTherapeutics said it had finalised a dosing level at which the technology will be used which maintains the viability of the skin cells.

It has also received confirmation of the modifying property of SkinBiotix on the protein composition of the skin, increasing the expression of a protein called Claudin 4 that help protect the skin.

Early-stage commercial discussions have also begun with both would-be licensees and manufacturers.

"Operationally, we are on track,” said CEO O’Neill. “The development programmes are progressing well, we are generating further scientific data on SkinBiotix confirming its suitability for application to skin, and industry awareness of our technology is growing."

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use